In particular, advanced NSCLC patients with driver mutations, including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement, can benefit from treatment with MTTs [1,2,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.